Crystal Research Associates, LLC Issues Executive Informational Overview (EIO) on CardioComm Solutions, Inc.

NEW YORK, NY--(Marketwired - Aug 6, 2013) -  Crystal Research Associates, LLC announced today that it has issued an Executive Informational Overview^® (EIO) on CardioComm Solutions, Inc. (TSX VENTURE: EKG). The full 60-page report is available on Crystal Research Associates' website at www.crystalra.com.

CardioComm Solutions specializes in software engineering of information management systems and integration of bio-monitoring devices for the cardiac and telemedicine markets. The Company's integrated electrocardiogram (ECG) and arrhythmia monitoring products and services enable patients, medical professionals, and healthcare experts to quickly and easily manage patient information and ECG recordings in a secure, reliable environment from anywhere in the world -- specifically to record, view, analyze, and store patients' ECGs for diagnosis and treatment of cardiac disorders.

Rated as the best enabling technology for cardiac rhythm monitoring in 2012 by Frost & Sullivan, CardioComm Solutions' technology is used in a number of software and hardware products dedicated to improving the quality of life for anyone who has been diagnosed with, or who may be at risk for, cardiovascular disease.

The Company recently introduced a new handheld ECG recording device, the HeartCheck™ PEN ECG, which represents the first in-home, consumer-targeted health monitoring technology for over-the-counter (OTC) markets in the past 30 years. The HeartCheck™ devices (which also include a prescription HeartCheck™ Handheld ECG Monitor) are supported by software programs and patent-pending "SMART Monitoring services," which the Company has developed to enable 24/7 patient monitoring and objective medical interpretation, with the capacity for integrating ECG reporting into existing electronic medical records (EMRs), among other innovative features.

Be the first to hear about Crystal Research's new report releases and upcoming media coverage. Follow us on Twitter at http://twitter.com/crystalresearch or visit http://crystalra.com/blog/ for more coverage.

About Crystal Research Associates, LLC

Crystal Research Associates, LLC (www.crystalra.com) is an independent research firm that has provided institutional-quality research on small- and mid-cap companies for the past decade. The firm is led by veteran Wall Street sell-side analyst Jeffrey Kraws, who is well known by the international financial media for his years of work on Wall Street as well as for providing consistent award-winning analyses and developing long-term relationships on both the buy-side and sell-side. He has been consistently ranked on Wall Street among the Top Ten Analysts for pharmaceutical stock performance in the world for almost two decades as well as ranked as the Number One Stock Picker in the world for pharmaceuticals by Starmine and for estimates from Zacks. Additionally, Mr. Kraws has been 5-Star ranked for top biotechnology stock performance by Starmine.

Crystal Research Associates' unique and novel product, the Executive Informational Overview^® (EIO), is free of investment ratings, target prices, and forward-looking financial models. The EIO presents a crystal clear, detailed report on a company (public or private) in a manner that is easily understood by the Wall Street financial community. The EIO details a company's product/technology/service offerings, market size(s), key intellectual property, leadership, growth strategy, competition, risks, financial statements, key events, and other such fundamental information. Crystal Research Associates has offices in New York City and West Palm Beach. Crystal Research Associates has been compensated by the Company in cash of twelve thousand U.S. dollars and equity of four hundred fifty thousand shares of CardioComm Solutions, Inc. for its services in creating this report, for updates, and for printing costs.

Forward-Looking Safe Harbor Statement

Statements in this news release regarding future financial and operating results, potential applications of the Company's technology, opportunities for the Company, and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words "will," "believes," "plans," "anticipates," "expects," "estimates," and similar expressions) should also be considered forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including limited operating history, need for future capital, and economic conditions generally. Additional information on potential factors that could affect results and other risks and uncertainties are detailed from time to time in the Company's periodic news and reports.

These statements, and other forward-looking statements, are not guarantees of future performance and involve risks and uncertainties. Crystal Research Associates assumes no obligation to update any of the forward-looking statements in this release.